AuraSense Therapeutics Closes Second Tranche of Series B Financing

AuraSense Therapeutics, a Skokie, Illinois-based biopharmaceutical company, closed the second tranche of its Series B financing.

The investment, whose terms were not disclosed, adds to the initial Series B round completed in December 2011. Investors include AbbVie, Inc. and individual investors Patrick Ryan, founder of Aon; David Walt, co-founder of Illumina; Boon Hwee Koh, Director of Agilent Technologies and former Chairman of Singapore Airlines, and Craig Mundie, Chief Research and Strategy Officer of Microsoft.

The company intends to use the funds to take its first spherical nucleic acid (SNA™) constructs through the preclinical development phase.

Founded by Professors Chad A. Mirkin and C. Shad Thaxton of Northwestern University, AuraSense Therapeutics is dedicated to developing and commercializing SNA constructs as gene regulation and modulation agents for a variety of diseases, including applications in oncology, dermatology, neurology, and for immune disorders.



Join the discussion